Evidence map›Paper›PMID 32389660›Full record

ArticleHuman pathology2020

Telomere lengths differ significantly between small-cell neuroendocrine prostate carcinoma and adenocarcinoma of the prostate.

Christopher M Heaphy, Michael C Haffner, Mindy K Graham, David Lim, Christine Davis, Eva Corey, Jonathan I Epstein, Mario A Eisenberger, Hao Wang, Angelo M De Marzo and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Human pathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Role of telomere length in human carcinogenesis (Review).International journal of oncology · 2023
    Review
  3. Race Differences in Telomere Length in Benign Prostate Biopsies and Subsequent Risk of Prostate Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Christopher M HeaphyDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, 21287, USA. Electronic address: heaphyc@bu.edu.
Michael C HaffnerDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Mindy K GrahamDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA; Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
David LimDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Christine DavisDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Eva CoreyDepartment of Urology, University of Washington, Seattle, WA, 98195, USA.
Jonathan I EpsteinDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA; Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, 21287, USA.
Mario A EisenbergerDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA; Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Hao WangDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Angelo M De MarzoDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA; Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, 21287, USA.
Alan K MeekerDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA; Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, 21287, USA.
Tamara L LotanDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA; Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, 21287, USA.
Johns Hopkins University · USUniversity of Washington · US

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI WILLIAM George NELSON · 1985 to 2026
$208.6M
TRANSGENIC MODELS FOR PROSTATE CANCER AND AUTOIMMUNITYP50CA058236 · NCI · JOHNS HOPKINS UNIVERSITY · PI DENMEADE, SAMUEL R · 1992 to 2020
$43.9M
Establishing in vitro carcinoma models of the Alternative Lengthening of Telomeres pathway to elucidate molecular mechanisms and identify therapeutic vulnerabilitiesF32CA213742 · NCI · JOHNS HOPKINS UNIVERSITY · PI GRAHAM, MINDY KIM · 2017 to 2018
$118k
NCI NIH HHS F32 CA213742NCI NIH HHS P30 CA006973NCI NIH HHS P50 CA058236
6 · The paper itself

Abstract

Small-cell neuroendocrine carcinoma (SCNC) of the prostate is an aggressive subtype with frequent TP53 mutation and RB1 inactivation; however, the molecular phenotype remains an area of investigation. Here, we compared telomere lengths in prostatic SCNC and usual-type prostatic adenocarcinoma (AdCa). We studied 32 cases of prostatic SCNC (including 11 cases with concurrent AdCa) and 347 cases of usual-type AdCa on tissue microarrays. Telomere lengths in tumor cells were qualitatively compared with those in normal cells using a telomere-specific fluorescence in situ hybridization assay. ERG, PTEN, and TP53 status were assessed in a proportion of cases using genetically validated immunohistochemistry protocols. Clinicopathological and molecular characteristics of cases were compared between the telomere groups using the chi-square test.A significantly higher proportion of prostatic SCNC cases (50%, 16/32) showed normal/long telomeres compared with AdCa cases (11%, 39/347; P < 0.0001). In 82% (9/11) of cases with concurrent SCNC and AdCa, the paired components were concordant for telomere length status. Among AdCa cases, the proportion of cases with normal/long telomeres significantly increased with increasing tumor grade group (P = 0.01) and pathologic stage (P = 0.02). Cases with normal/long telomeres were more likely to be ERG positive (P = 0.04) and to have TP53 missense mutation (P = 0.01) than cases with short telomeres.Normal or long telomere lengths are significantly more common in prostatic SCNC than in AdCa and are similar between concurrent SCNC and AdCa tumors, supporting a common origin. Among AdCa cases, longer telomere lengths are significantly associated with high-risk pathologic and molecular features.

Indexed as

AdenocarcinomaCarcinoma, NeuroendocrineCarcinoma, Small CellHumansMaleMiddle AgedProstatic NeoplasmsTelomereAdenocarcinomaNeuroendocrineProstate cancerSmall-cell carcinomaTelomeres

Identifiers

PMID32389660
PMCPMC7321874
OpenAlexW3022650203

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.